Go Deep
Denali Therapeutics Inc.
Denali Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,002 | -6.5 | 3.52 | 0.04 | 1,752.30 |
| Oct 2026 | 19,150 | -6.3 | 3.42 | 0.04 | 1,696.71 |
| Oct 2026 | 19,018 | -6.6 | 3.51 | 0.04 | 1,741.59 |
| Oct 2026 | 19,222 | -6.2 | 3.37 | 0.04 | 1,667.93 |
| Oct 2026 | 19,102 | -6.4 | 3.45 | 0.04 | 1,710.49 |
| Oct 2026 | 18,854 | -6.7 | 3.62 | 0.04 | 1,794.87 |
| Oct 2026 | 18,924 | -6.6 | 3.58 | 0.04 | 1,766.79 |
| Oct 2026 | 18,929 | -6.6 | 3.57 | 0.04 | 1,761.33 |
Denali Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,604,000.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -127,553,000.0 | -128,447,000.0 | -128,549,000.0 | -126,902,000.0 |
| EPS | -0.7 | -0.7 | -0.7 | -0.7 |
Denali Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 330,531,000.0 | 108,463,000.0 | — |
| Net Profit | -512,540,000.0 | -422,773,000.0 | -145,224,000.0 | -325,991,000.0 | — |
| EPS | -3.0 | -2.6 | -1.1 | -2.6 | — |
Denali Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,144,854,000.0 | 1,374,180,000.0 | 1,153,917,000.0 | 1,460,242,000.0 | — |
| Total Liabilities | 131,093,000.0 | 144,496,000.0 | 122,963,000.0 | 417,812,000.0 | — |
| Total Equity | 1,013,761,000.0 | 1,229,684,000.0 | 1,030,954,000.0 | 1,042,430,000.0 | — |
Owes vs Owns
Denali Therapeutics Inc. owed $0.28 for every $1 it owned in Jun 2026, down from $0.29 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.28× | 0.11× | 0.11× | 0.11× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Denali Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 75.8%Fixed assets (tangible) 10.5%Long-term investments 8.6%Other assets 4.9%
How it's funded — Dec 2025
Short-term debt 0.8%Long-term debt 2.4%Other liabilities 7.9%Shareholders' equity 88.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 867.9 | 832.3 | 1,034.5 | 1,336.2 |
| Receivables | 2.2 | 2.2 | 3.4 | 9.3 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 119.9 | 125.6 | 71.6 | 74.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 98.3 | 359.4 | 0.0 | 0.0 |
| Other assets | 56.5 | 54.7 | 44.3 | 40.2 |
| Liabilities & equity | ||||
| Short-term debt | 9.5 | 12.0 | 7.3 | 7.3 |
| Long-term debt | 27.2 | 36.7 | 45.0 | 53.0 |
| Payables | 3.3 | 11.1 | 9.5 | 2.8 |
| Other liabilities | 91.0 | 84.7 | 61.2 | 354.7 |
| Shareholders' equity | 1,013.8 | 1,229.7 | 1,031.0 | 1,042.4 |
| Net tangible assets | 1,013.8 | 1,229.7 | 1,031.0 | 1,042.4 |
Denali Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -412,600,000.0 | -347,694,000.0 | -357,991,000.0 | -244,716,000.0 |
| Investing Activities | 255,281,000.0 | -88,756,000.0 | 249,308,000.0 | -141,387,000.0 |
| Financing Activities | 189,216,000.0 | 484,304,000.0 | 17,820,000.0 | 310,670,000.0 |